Crossmark

BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer

Crossref DOI link: https://doi.org/10.1038/s41388-019-0815-5

Published Online: 2019-04-17

Published Print: 2019-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Coleman, Daniel J.

Gao, Lina

King, Carly J.

Schwartzman, Jacob https://orcid.org/0000-0002-2640-8181
Urrutia, Joshua https://orcid.org/0000-0003-2171-0936
Sehrawat, Archana

Tayou, Junior

Balter, Ariel

Burchard, Julja

Chiotti, Kami E.

Derrick, Daniel S. https://orcid.org/0000-0003-3305-3507
Sun, Duanchen

Xia, Zheng https://orcid.org/0000-0003-3364-8324
Heiser, Laura M. https://orcid.org/0000-0003-3330-0950
Alumkal, Joshi J. https://orcid.org/0000-0003-1278-0166
License Information

Text and Data Mining valid from 2019-04-17
More Information

Article History

Received: 9 November 2018

Revised: 15 March 2019

Accepted: 19 March 2019

First Online: 17 April 2019

Compliance with ethical standards

:

: JJA has performed consulting or held an advisory role with Astellas Pharma, Bayer, and Janssen Biotech, Inc. OHSU has received institutional research funding from Aragon Pharmaceuticals Inc., Astellas Pharma, Norvartis, Zenith Epigenetics Ltd, and Gilead Sciences Inc. These interests had no role in the design or conduct of this study. The remaining authors declare that they have no conflict of interest.